Post-acute infection syndromes (PAIS) may develop after acute viral disease1. Infection with SARS-CoV-2 can result in the development of a PAIS known as “Long COVID” (LC). Individuals with LC frequently report unremitting fatigue, post-exertional malaise, and a variety of cognitive and autonomic dysfunctions2–4; however, the biological processes associated with the development and persistence of these symptoms are unclear. Here, 273 individuals with or without LC were enrolled in a cross-sectional study that included multi-dimensional immune phenotyping and unbiased machine learning methods to identify biological features associated with LC. Marked differences were noted in circulating myeloid and lymphocyte populations relative to matched controls, as well as evidence of exaggerated humoral responses directed against SARS-CoV-2 among participants with LC. Further, higher antibody responses directed against non-SARS-CoV-2 viral pathogens were observed among individuals with LC, particularly Epstein-Barr virus. Levels of soluble immune mediators and hormones varied among groups, with cortisol levels being lower among participants with LC. Integration of immune phenotyping data into unbiased machine learning models identified key features most strongly associated with LC status. Collectively, these findings may help guide future studies into the pathobiology of LC and aid in developing relevant biomarkers.

Posted at the top of the article: "We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply. "

  • Björn Tantau
    2•9 months ago

    Can anyone give a tldr? Long Covid has made my brain too stupid to understand this kind of article.

    • @[email protected]
      6•9 months ago

      I’m not an expert but I feel for you and will try my TLDR.

      They did a study of almost 300 people. They split these into two groups, some with long COVID and some without.

      They then tried to determine if those with long COVID had a signature in their antibodies. That’s what “immuno phenotyping” means … finding a unique pattern in antibody types and responses.

      They did indeed find those signatures or patterns. Specifically, people with long COVID had more of specific types of antibodies and faster antibody responses to COVID and other viruses like Epstein Barr.

      These differences between these two groups might help to identify and diagnose long COVID.

      Further study is recommended (edit: almost all papers end with this recommendation)